RSS   Newsletter   Contact   Advertise with us
Post Online Media

MyoKardia appoints Marc Semigran as CMO

MyoKardiaMyoKardia, a company focused on developing innovative therapeutics to treat genetic heart disease, announced that Marc Semigran has joined the company as chief medical officer.

Most recently, Dr. Semigran led the Massachusetts General Hospital Heart Failure and Cardiac Transplant Program as section head and medical director, from 2004 to 2016.

In addition, Dr. Semigran was principal investigator of the Harvard Regional Clinical Center of the National Heart, Lung, and Blood Institute Heart Failure Network.

Dr. Semigran has been a member of the internal medicine and cardiology staff of Massachusetts General for more than 25 years and is an associate professor at Harvard Medical School.


 LATEST MOVES FROM California 





More inside POST
 
 

We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy